@article {Beck2021.03.02.433405, author = {Adam Beck and Vedrana Marin and Jay Deng and Irina Madorsky and Bin Ren and Yichen Guo and Dan Neal and Gerry Shaw}, title = {A study of the neuronal injury biomarkers pNF-H and UCHL1 in serum, CSF and urine in a cohort of thoracic endovascular aortic repair (TEVAR) patients}, elocation-id = {2021.03.02.433405}, year = {2021}, doi = {10.1101/2021.03.02.433405}, publisher = {Cold Spring Harbor Laboratory}, abstract = {A collection of longitudinal serum, cerebrospinal fluid (CSF) and urine samples were collected from a cohort of 50 patients undergoing thoracic endovascular aortic repairs (TEVAR). Samples were taken multiple time per day out to 5 days post operation and were probed with novel electrochemiluminescent assays specific for the phosphorylated axonal form of the major neurofilament subunit NF-H (pNF-H) and for ubiquitin C-terminal hydrolase 1 (UCHL1). Control blood samples showed small signals for pNF-H and in some cases rather larger signals for UCHL1. The presence of UCHL1 in these control blood samples was convincingly verified by western blotting with multiple well characterized UCHL1 antibodies and by mass spectroscopy. Elevated levels of both pNF-H and UCHL1 in blood and CSF in recovering TEVAR patients were associated with poorer outcomes. In particular release of UCHL1 into blood over several hours following TEVAR and peaking at any time over 1 ng/ml was a very strong predictor of patient death and was associated with renal failure and spinal cord ischemia (SCI). An unexpected finding was that high levels of UCHL1 were detected in certain urine samples, again in association with SCI, renal failure and poor patient outcome. We also present epitope mapping data on the UCHL1 monoclonal antibodies used including data on the widely used commercially available MCA-BH7. These studies suggest that measurement of the levels of both proteins in the blood, CSF and urine of TEVAR patients may be of clinical utility. However this study also raises questions about the origin and significance of UCHL1 both in control blood, in patient blood samples and in urine.Competing Interest StatementGerry Shaw is CEO and part owner of EnCor Biotechnology Inc., where the assays described were developed and run. EnCor may therefore benefit slightly from sales and equity growth. No other COIs.}, URL = {https://www.biorxiv.org/content/early/2021/03/02/2021.03.02.433405}, eprint = {https://www.biorxiv.org/content/early/2021/03/02/2021.03.02.433405.full.pdf}, journal = {bioRxiv} }